New prediction model helps identify epilepsy risk after stroke

Researchers from 15 countries, led by Amsterdam UMC, have developed a way to predict which patients are at risk of epilepsy after a cerebral venous sinus thrombosis (CVT). CVT is a type of stroke that typically affects women between the ages of 20 and 50. The prediction model is now available worldwide free of charge and research it is based on is published today in JAMA Neurology. 

We hope that as many physicians as possible will use this score to better treat and educate CVT patients across the world."

Jonathan Coutinho, lead researcher and neurologist at Amsterdam UMC

CVT occurs when a clot blocks the veins that drain blood from the brain, preventing blood from draining properly. In the Netherlands, it affects 250 people every year, three-quarters of whom are women, occurring mainly in younger people, between 20 and 50 years old. One in ten of these patients develops epilepsy after the stroke, often months later, as a result of the damage to their brain damage. 

"These patients usually have to take medication for life and epilepsy has, naturally, a negative impact on their quality of life. Until now, it was not possible to predict which patients have the highest risk of developing epilepsy after sinus thrombosis," says Coutinho. 

Due to the relative rarity of the disease, it is difficult to collect data from a sufficient number of patients. The Amsterdam UMC team therefore collaborated with researchers from 15 countries, including more than 10 centres in the United States. Together, they analysed data from over 2,000 patients from 1994 to 2022, focusing on data from patients who developed epilepsy between 7 days and 3 years after their stroke. 

By predicting which patients are at a greater risk of developing epilepsy, healthcare professionals also learn which patients are likely to need epilepsy medication in the long term. This facilitates the development of personalised treatment plans and allows the treatment team to prepare the patient for possible epileptic seizures in the future. The patient can then take precautions, for example by no longer driving a car. 

"Because it mainly affects women at an age when they are in the middle of their careers and maybe starting a family, it is important for them to know if they should take epilepsy into account," explains Coutinho. 

 "We hope that this score will also help healthcare providers in the guidance of CVT patients and that it will contribute to follow-up research into treatment with anti-seizure medication. Ultimately, we want to completely prevent epilepsy after CVT," he adds. This research and the worldwide online availability of the prediction model show the power of international academic collaboration, especially in rare diseases where there are few patients per country. 

How does the DIAS3 scoring prediction model work? 

On the basis of 6 indicators, it is possible to predict the risk of epilepsy in an individual patient after this type of stroke. These data are already routinely collected in patients with CVT. The 6 indicators used in the model are (1) age, (2) a cerebral hemorrhage, (3) seizures in the first 7 days, (4) status epilepticus (epileptic seizure that does not stop on its own) in the first 7 days, (5) subdural hematoma (hemorrhage between the outer two membranes of the brain) and (6) a surgical procedure in which the skull is (partially) lifted to prevent swelling of the brain. With these data, the computational model can predict each individual patient's risk of epilepsy. 

The DIAS3 score is accessible online to all healthcare providers worldwide via the website of the International Cerebral Venous Thrombosis Consortium .

Source:
Journal reference:

Lindgren, E., et al. (2024). Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis. JAMA Neurology. doi.org/10.1001/jamaneurol.2024.3481.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New risk score identifies heart disease risk in kidney transplant patients